What Entyvio – Initial treats
Entyvio (vedolizumab) is a biologic medication specifically designed to treat moderate to severe ulcerative colitis (UC) and Crohn’s disease. By targeting and inhibiting a specific protein involved in the inflammatory process of the gut, Entyvio is directed at reducing symptoms and inducing and maintaining remission in these chronic inflammatory bowel diseases.
Benefits of Entyvio
The treatment goals in the conditions Entyvio is approved to treat include reduced gastrointestinal symptoms, better management of disease flares, and increased rates of remission. Whether an individual patient reaches them varies, and is assessed by the prescribing clinician. By specifically targeting the gut, Entyvio minimizes systemic side effects and provides a more focused approach to treating inflammatory bowel disease.
Possible Side Effects of Entyvio
Some patients experience side effects, including headaches, joint pain, and upper respiratory infections. Infusion-related reactions, such as fever or chills, can also occur. Serious side effects may include an increased risk of infections, liver problems, and allergic reactions. It’s important to stay in close contact with your healthcare provider and report any unusual symptoms.
How infusion works at Prime
Entyvio – Initial is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Entyvio – Initial, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Entyvio Work?
Entyvio works by targeting the integrin α4β7, a protein that helps white blood cells move into the gut lining, where they cause inflammation. By binding to this protein, Entyvio blocks the migration of these cells into the inflamed tissue, thereby reducing inflammation and helping to control the symptoms of UC and Crohn’s disease. Entyvio is administered through intravenous infusion, typically every eight weeks after the initial doses.
Who is Entyvio For?
Entyvio is suitable for adults with moderate to severe ulcerative colitis or Crohn’s disease who have not responded adequately to conventional therapies, such as corticosteroids, immunomodulators, or other biologics. It is often prescribed for patients seeking a targeted treatment that focuses specifically on gut inflammation with minimal systemic effects.